The rate and amount of weight loss varies depending on the individual’s starting weight, adherence to the program, and specific medications used. On average, patients on GLP-1 medication can lose 15%-20% of their body weight in a year.* It is important to remember that results and timelines can vary.
New England Journal Of Medicine
*In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, those on semaglutide lost on average 14.9% of their weight as opposed to 2% of the placebo group. Both groups followed a reduced-calorie diet, increased physical activity, and monthly nutritional counseling. Starting semaglutide (Wegovy®) dosage was 0.25mg per week, increasing to 2.4mg. The trial was overseen and sponsored by Novo Nordisk.
New England Journal of Medicine
*In a 72-week placebo-controlled study of 2,539 obese and overweight non-diabetic adults with weight-related conditions, those on the highest dose of tirzepatide lost on average roughly 20% of their weight as opposed to 3.1% of the placebo group. Both groups followed healthy lifestyle changes. Starting tirzepatide dosage was 2.5mg per week, increasing to 10mg. The trial was overseen and sponsored by Eli Lilly.